Wegner, Steven <br/><br/>
Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.  [electronic resource] 

 -  Pediatrics  Dec 2004 
 - 1612-9 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>1098-4275 
<br/><br/><label>Standard No.: </label>10.1542/peds.2004-0959  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Ambulatory Care--economics<br/>Antibodies, Monoclonal--economics<br/>Antibodies, Monoclonal, Humanized<br/>Antiviral Agents--economics<br/>Bronchiolitis--economics<br/>Cohort Studies<br/>Cost Savings<br/>Cost-Benefit Analysis<br/>Direct Service Costs<br/>Health Care Surveys<br/>Hospital Mortality<br/>Hospitalization--economics<br/>Humans<br/>Infant<br/>Infant, Newborn<br/>Infant, Premature<br/>Medicaid--statistics & numerical data<br/>Models, Economic<br/>North Carolina<br/>Palivizumab<br/>Regression Analysis<br/>Respiratory Syncytial Virus Infections--economics<br/>Respiratory Syncytial Virus, Human